Editas Medicine Plans Human Trial After Gene Therapy Slashed LDL 90% in Primate Study
Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates
Editas: Q3 Earnings Snapshot
Editas Medicine Announces Third Quarter 2026 Results and Business Updates
Editas Medicine Q3 EPS $(0.15) Beats $(0.18) Estimate, Sales $10.365M Beat $4.460M Estimate
Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
Editas: Downgrade To 'Hold' On Reni-Cel Discontinuation SCD/TDT And EDIT-401 Strategic Shift
Wells Fargo Upgrades Editas Medicine to Overweight, Raises Price Target to $6
Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
Editas Medicine Receives Approval To Initiate Its Phase 1/2 Strive Clinical Trial Of EDIT-401 In Patients With Heterozygous Familial Hypercholesterolemia In Australia
Guggenheim Upgrades Editas Medicine to Buy, Announces $5 Price Target
Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy
Editas Medicine Reports Inducement Grants to New Chief Medical Officer
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?
Editas: Slow Progress Doesn't Mean No Progress For In-Vivo Gene Editor
Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine Files Prospectus For Offering $400M Mixed Shelf
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.